| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Atara Biotherapeutics, Inc. (ATRA) has 3 insiders with recent SEC Form 4 filings, including 0 buys and 17 sells. ATRA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.32M | $14.15M | - | |
| CEO | 143.1K | $1.53M | - | |
| Other | 52.0K | $555.9K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2019 | Marcus Joel S68 | Director | Sell | 20,000 | $38.25 | $765,000.00 | -2.2% | |
| Mar 15, 2019 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 7,800 | $39.48 | $307,953.00 | -0.8% | |
| Mar 1, 2019 | Newell Joe85 | Chief Tech. Operations Officer | Sale+OE | 1,500 | $36.13 | $54,202.00 | -1.6% | |
| Feb 28, 2019 | Marcus Joel S68 | Director | Sale+OE | 62,590 | $36.07 | $2,257,621.30 | -89.3% | |
| Feb 28, 2019 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 7,800 | $36.14 | $281,891.00 | -0.8% | |
| Feb 15, 2019 | Porter Derrell | SVP, Head Of Global Commercial | Sale+OE | 5,909 | $40.00 | $236,360.00 | -21.4% | |
| Feb 15, 2019 | Haqq Christopher | EVP, R&D &Chief Scientific Of | Sell | 775 | $39.59 | $30,682.25 | -0.3% | |
| Feb 12, 2019 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 7,800 | $38.77 | $302,367.00 | -1.1% | |
| Feb 11, 2019 | Haqq Christopher | EVP, R&D &Chief Scientific Of | Sell | 13,975 | $38.55 | $538,736.25 | -4.9% | |
| Feb 6, 2019 | Haqq Christopher | EVP, R&D &Chief Scientific Of | Sell | 12,375 | $38.62 | $477,921.52 | -2.2% |